Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.

Burden, A D; Okubo, Y; Zheng, M; Thaçi, D; van de Kerkhof, P; Hu, N; Quaresma, M; Thoma, C; Choon, S E

Burden, A D; Okubo, Y; Zheng, M; Thaçi, D; van de Kerkhof, P; Hu, N; Quaresma, M; Thoma, C; Choon, S E.

Afiliação

Burden AD; School of Infection and Immunity, University of Glasgow, Glasgow, UK.
Okubo Y; Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Zheng M; Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
van de Kerkhof P; Department of Dermatology, Radboud University, Nijmegen, The Netherlands.
Hu N; Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China.
Quaresma M; Boehringer Ingelheim International GmbH, Ingelheim, Germany.
Thoma C; Boehringer Ingelheim International GmbH, Biberach, Germany.
Choon SE; Department of Dermatology, Hospital Sultanah Aminah, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia.

Exp Dermatol ; 32(8): 1279-1283, 2023 08.

Article em En | MEDLINE | ID: mdl-37140190

Assuntos

Psoríase; Humanos; Resultado do Tratamento; Anticorpos Monoclonais Humanizados/uso terapêutico; Pele

Palavras-chave

autoinflammatory disorders; clinical trial; psoriasis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Exp Dermatol Assunto da revista: DERMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google